PERITONEAL MET PATIENTS:
I know there has been a lot of interest in the oncolytic virus + PD(L)1 inhibitor strategy after I recently signed up for the NCT02636036 trial. I also wanted to post this because peri mets can be resistant to chemotherapy.
It is one experimental strategy to try to convert a cold MSS tumor into a highly inflamed tumor which "looks more like" a MSI-high CRC or HPV+ tumor in that regard (all of which often respond to PD(L)1 inhibitors).
This new Oncolytic virus + PDL1 inhibitor trial is opening in January. Trial sites so far: NYC and Buffalo, NY. It is specifically recruiting CRC patients with peritoneal mets.
Their inclusion criteria on paper looks a bit strict (can you join after failing FOLFIRI or do you need to at least try TAS/Stivarga first?) but you can see how strictly they interpret it by presenting your medical situation and seeing what they say.https://clinicaltrials.gov/ct2/show/NCT02963831
6/4/2012 Dx Stage 3C CRC @ 40 yo. MSS, KRAS-WT, BRAF-WT, p53-mut
8/13 Enlarged lymphs - Stable
10/14 Stage IV. Lung & Lymph mets. 5-FU+bev
11/15 FOLFIRI + bev
11/16 Signs of FOLFIRI resistance (Lymph mets)
1/17 Palliative radiation for resistant mets
2/17 FOLFIRI + bev + Maraviroc (off-label)
3/17 FOLFIRI + Erbitux + Maraviroc (off-label)MSS-CRC Clinical Trial Finder: http://trialfinder.fightcrc.org/2016 Colondar 2.0 ModelDK37 Science Posts List